80%Confidence
0Views
SEC EDGARSource
2026-04-07Date
Summary
Soleno Therapeutics Inc filed an 8-K, potentially announcing clinical trial results, regulatory milestones, or financing activities in the biotech sector. Such filings often drive volatility in small-cap biotech stocks based on development updates.
Actionable: Analyze the 8-K for news on drug development progress or partnerships that could impact Soleno's valuation.
AI Confidence: 80%
Data Points
companySOLENO THERAPEUTICS INC (SLNO) (CIK 0001484565)
form8-K
date2026-04-07
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now